10x Genomics (TXG) Shares Outstanding (2018 - 2026)

10x Genomics has reported Shares Outstanding (Entity) for 9 years, with the latest figure at $129.0 million in Q1 2026.

• Quarterly Shares Outstanding (Entity) rose 4.75% year-over-year to $129.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $129.0 million (up 4.75% YoY) and the FY2025 annual result came in at $127.7 million, up 4.42% from the prior year.
• Shares Outstanding (Entity) advanced to $129.0 million in Q1 2026 per TXG's latest filing, from $127.7 million in the prior quarter.
• Over five years, Shares Outstanding (Entity) peaked at $129.0 million in Q1 2026 and troughed at $113.3 million in Q1 2022.
• A 5-year average of $120.1 million and a median of $119.7 million in 2024 frame the typical range for Shares Outstanding (Entity).
• The sharpest annual moves came in 2022 and 2026: Shares Outstanding (Entity) increased 2.38% in 2022, then rose 4.75% in 2026.
• Over 5 years, Shares Outstanding (Entity) stood at $115.2 million in 2022, then grew by 3.39% to $119.1 million in 2023, then advanced by 2.68% to $122.3 million in 2024, then climbed by 4.42% to $127.7 million in 2025, then rose by 1.02% to $129.0 million in 2026.
• According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $129.0 million, $127.7 million, and $126.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.